Skip to main content
Erschienen in: Medical Oncology 4/2010

01.12.2010 | Original Paper

Pathologic complete response of a solitary melanoma brain metastasis after local ablative radiation therapy: case report

verfasst von: Steven Register, James W. Clarke, Abhik Ray Chaudhury, Simon S. Lo

Erschienen in: Medical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

A 73-year-old female with malignant melanoma metastatic to her left frontal lobe status post-gross total resection of the metastasis, whole brain radiotherapy, and Gamma Knife-based stereotactic radiosurgery for local recurrence presented with an area of increasing enhancement on follow-up magnetic resonance imaging (MRI) and hypermetabolic lesions on 18-fluorodeoxyglucose positron emission tomography/computerized tomography (18FDG PET/CT) of the brain suspicious for tumor recurrence. Surgical resection of the lesion was performed showing radiation necrosis with no evidence of tumor. The patient was alive 1 year after her second craniotomy. This case illustrates that despite being perceived as a radioresistant histology, complete local eradication of melanoma is possible with ablative dose regimens. Prolonged survival is possible in patients with limited metastatic melanoma if local tumor control is achieved.
Literatur
1.
Zurück zum Zitat Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39(1):25–30.CrossRefPubMed Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39(1):25–30.CrossRefPubMed
2.
Zurück zum Zitat Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191–7.CrossRefPubMed Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191–7.CrossRefPubMed
3.
Zurück zum Zitat Belohlavek O, Simonova G, Kantorova I, Novotný J Jr, Liscák R. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imaging. 2003;30:96–100.CrossRefPubMed Belohlavek O, Simonova G, Kantorova I, Novotný J Jr, Liscák R. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imaging. 2003;30:96–100.CrossRefPubMed
4.
Zurück zum Zitat Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861–7.PubMed Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861–7.PubMed
5.
Zurück zum Zitat Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kälkner KM, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45(7):870–5.CrossRefPubMed Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kälkner KM, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45(7):870–5.CrossRefPubMed
Metadaten
Titel
Pathologic complete response of a solitary melanoma brain metastasis after local ablative radiation therapy: case report
verfasst von
Steven Register
James W. Clarke
Abhik Ray Chaudhury
Simon S. Lo
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9360-3

Weitere Artikel der Ausgabe 4/2010

Medical Oncology 4/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.